Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study

Published:2022-09 Issue:9 Volume:44 Page:1237-1247
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sohn Winnie,Winkle Peter,Neutel Joel,Wu You,Jabari Freeman,Terrio Caitlin,Varrieur Tracy,Wang Jingying,Hellawell Jennifer

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. Country Profiles: Japan,2019

2. High-risk atherosclerotic cardiovascular disease in a real-world employed Japanese population: prevalence, cardiovascular event rates, and costs;Davis;J Atheroscler Thromb,2015

3. Estimating years of life lost due to cardiovascular disease in Japan;Arai;Circ J,2019

4. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies;Danesh;Circulation,2000

5. Apolipoprotein(a) isoforms and the risk for vascular disease: systematic review of 40 studies involving 58,000 participants;Erqou;J Am Coll Cardiol,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein(a): Emerging insights and therapeutics;American Journal of Preventive Cardiology;2024-06

2. Management of dyslipidemia in coronary artery disease: the present and the future;Coronary Artery Disease;2024-04-29

3. Elevated Lp(a): Guidance for Identifying and Managing Patients;Southern Medical Journal;2024-04

4. Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference;Current Opinion in Cardiology;2024-03-27

5. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?;International Journal of Molecular Sciences;2024-03-21